Article: Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results

Purpose: To report on the anatomic and visual acuity response after intravitreal bevacizumab injection in patients with macular edema due to non-ischemic central retinal vein occlusion (CRVO).

Methods: In a retrospective study, 21 consecutive patients (21 eyes) with non-ischemic CRVO underwent, on average, 3.7 intravitreal bevacizumab injections (1.25 mg). Ophthalmic examination included best corrected visual acuity (BCVA) and central retinal thickness (CRT) at baseline and follow-up visits. Fluorescein angiography was performed at baseline and at follow-up visits if needed. Primary outcomes were change of BCVA and CRT.

Results: The follow-up period for all of the included patients was 12 months. The mean BCVA was unchanged at the 12-month examination (baseline: 20/160; 12 months: 20/160) (P = 0.771). The mean CRT decreased from 780 microm (standard deviation [SD] +/- 324 microm) at the baseline to a mean of 462 microm (SD +/- 248 microm) at 12 months (P < 0.05).

Conclusion: Intravitreal bevacizumab resulted in a significant decrease in CRT without significant improvement of visual acuity in patients with non-ischemic CRVO after a follow-up of 12 months.

Citing Articles

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario.

Simsek M, Citirik M, Ozates S, Ozkoyuncu D Indian J Ophthalmol. 2018; 66(6):831-836.

PMID: 29785994 PMC: 5989508. DOI: 10.4103/ijo.IJO_1259_17.

Correlation between macular ganglion cell-inner plexiform layer thickness and visual acuity after resolution of the macular edema secondary to central retinal vein occlusion.

Kim H, Yoon H, Kim S Int J Ophthalmol. 2018; 11(2):256-261.

PMID: 29487816 PMC: 5824081. DOI: 10.18240/ijo.2018.02.13.

SCORE2 Report 2: Study Design and Baseline Characteristics.

Scott I, VanVeldhuisen P, Ip M, Blodi B, Oden N, Figueroa M Ophthalmology. 2016; 124(2):245-256.

PMID: 27863843 PMC: 5272814. DOI: 10.1016/j.ophtha.2016.09.038.

Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: a retrospective review.

DeCroos F, Todorich B, Alshareef R, Khuthaila M, Fekrat S, Ho A J Ophthalmic Vis Res. 2015; 9(4):461-8.

PMID: 25709772 PMC: 4329707. DOI: 10.4103/2008-322X.150825.

Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel.

Gerding H, Mones J, Tadayoni R, Boscia F, Pearce I, Priglinger S Br J Ophthalmol. 2014; 99(3):297-304.

PMID: 25075121 PMC: 4345884. DOI: 10.1136/bjophthalmol-2014-305041.

References

1.

Pai S, Shetty R, Vijayan P, Venkatasubramaniam G, Yadav N, Shetty B . Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol. 2007; 143(4):601-6. DOI: 10.1016/j.ajo.2006.12.037. View

2.

Stahl A, Agostini H, Hansen L, Feltgen N . Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol. 2007; 245(10):1429-36. DOI: 10.1007/s00417-007-0569-6. View

3.

Matsumoto Y, Freund K, Peiretti E, Cooney M, Ferrara D, Yannuzzi L . Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina. 2007; 27(4):426-31. DOI: 10.1097/IAE.0b013e31804a7af2. View

4.

Hsu J, Kaiser R, Sivalingam A, Abraham P, Fineman M, Samuel M . Intravitreal bevacizumab (avastin) in central retinal vein occlusion. Retina. 2007; 27(8):1013-9. DOI: 10.1097/IAE.0b013e318050ca7c. View

5.

Iturralde D, Spaide R, Meyerle C, Klancnik J, Yannuzzi L, Fisher Y . Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006; 26(3):279-84. DOI: 10.1097/00006982-200603000-00005. View

6.

Costa R, Jorge R, Calucci D, Melo Jr L, Cardillo J, Scott I . Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007; 27(2):141-9. DOI: 10.1097/IAE.0b013e31802eff83. View

7.

Mohamed Q, McIntosh R, Saw S, Wong T . Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2007; 114(3):507-19, 524. DOI: 10.1016/j.ophtha.2006.11.011. View

8.

Schaal K, Hoh A, Scheuerle A, Schutt F, Dithmar S . [Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion]. Ophthalmologe. 2007; 104(4):285-9. DOI: 10.1007/s00347-007-1509-x. View

9.

Spandau U, Ihloff A, Jonas J . Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand. 2006; 84(4):555-6. DOI: 10.1111/j.1600-0420.2006.00740.x. View

10.

. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology. 1995; 102(10):1425-33. DOI: 10.1016/s0161-6420(95)30849-4. View

11.

Priglinger S, Wolf A, Kreutzer T, Kook D, Hofer A, Strauss R . Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007; 27(8):1004-12. DOI: 10.1097/IAE.0b013e3180ed458d. View

Intravitreal Bevacizumab Treatment of Macular Edema in Central Retinal Vein Occlusion: One-year Results